Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cocaine Abuse and Attention Deficit Disorder - 3

This study has been completed.
New York State Psychiatric Institute
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: November 3, 2005
Last verified: May 1995
The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder

Condition Intervention
Cocaine-Related Disorders
Drug: Bupropion

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Cocaine Abuse and Attention Deficit Disorder

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Craving
  • Drug use
  • ADHD symptoms
  • Improvement in functioning
  • Tolerability

Estimated Enrollment: 32
Study Start Date: May 1995
Estimated Study Completion Date: November 1998
Detailed Description:
To evaluate the safety and efficacy of methylphenidate and bupropion in treating individuals with adult Attention Deficit Disorder.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

current adult ADHD current cocaine dependence

Exclusion Criteria:

no current major depression

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000268

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute
Principal Investigator: Herbert Kleber, M.D. New York State Psychiatric Institute
  More Information Identifier: NCT00000268     History of Changes
Other Study ID Numbers: NIDA-09236-3  P50-09236-3 
Study First Received: September 20, 1999
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Cocaine-Related Disorders
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on October 26, 2016